The reported rate of major birth defects among deliveries to women with migraine ranged from 2.2% to 2.9% and the reported rate of miscarriage was 17%, which were similar to rates reported in women without migraine.In a study using data from the Swedish Medical Birth Register, live births to women who reported using triptans or ergots during pregnancy were compared with those of women who did not. Sumatriptan Succinate Injection is a serotonin (5-HTMost common adverse reactions (≥5% and >placebo) were injection site reactions, tingling, dizziness/vertigo, warm/hot sensation, burning sensation, feeling of heaviness, pressure sensation, flushing, feeling of tightness, and numbness (Pregnancy: Based on animal data, may cause fetal harm (See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.Sumatriptan Succinate Injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache.The maximum single recommended adult dose of Sumatriptan Succinate Injection for the acute treatment of migraine or cluster headache is 6 mg injected subcutaneously. Sumatriptan has been in use for the treatment of acute migraine headache for almost 2 decades.
La fréquence des effets indésirables peut être augmentée par l'association des triptans à des préparations contenant du millepertuis (Hypericum perforatum). Ces réactions vont de l'allergie cutanée aux réactions anaphylactiques. Copy the URL below and paste it into your RSS Reader application.DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. Patients who respond initially but whose migraine returns may take a further dose at any time in the next 24 hours provided that one hour has elapsed since the first dose. Do not use if particulates and discolorations are noted.Sumatriptan Succinate Injection is contraindicated in patients with:The use of Sumatriptan Succinate Injection is contraindicated in patients with ischemic or vasospastic CAD. 0,5 ml en seringue pré-remplie (verre) ; boîte de 1. 0,5 ml en seringue pré-remplie (verre) ; boîte de 4. The injection is intended to be given subcutaneously, and intramuscular or intravascular delivery must be avoided. The effect of sumatriptan on the protein binding of other drugs has not been evaluated.Following a 6-mg subcutaneous injection into the deltoid area of the arm in 9 males (mean age: 33 years, mean weight: 77 kg) the volume of distribution central compartment of sumatriptan was 50 ± 8 liters and the distribution half‑life was 15 ± 2 minutes.In vitro studies with human microsomes suggest that sumatriptan is metabolized by MAO, predominantly the A isoenzyme. ... BETOOLL 0-140PSI Fuel Injector Injection Pump Pressure Tester Gauge Kit Car Tools (Master) 4.4 out of 5 stars 605.


The risk increases if you are also taking other drugs that increase serotonin, so tell your doctor or pharmacist of all the drugs you take (see Drug Interactions section). En cas de surdosage, le patient doit être mis sous surveillance pendant au moins 10 heures et un traitement symptomatique standard doit être administré, si nécessaire. Sumatriptan injection side effects.

In offspring of pregnant rats treated orally with sumatriptan during organogenesis, there was a decrease in pup survival. Protect from light.Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).Inform patients that Sumatriptan Succinate Injection may cause serious cardiovascular side effects such as myocardial infarction or stroke. On pense que la dilatation et/ou la formation d'oedèmes au niveau de ces vaisseaux pourraient correspondre au mécanisme de la migraine chez l'homme. Les données concernant l'interaction du sumatriptan avec les médicaments contenant de l'ergotamine ou un autre triptan/agoniste 5-HT1sont limitées. If your symptoms are only partly relieved or your headache returns, 2 hours after the injection you may switch to sumatriptan taken by mouth instead of using a second injection. Proportion of Patients with Pain Relief and Relief of Migraine Symptoms after 1 and 2 Hours of Treatment in Studies 2 and 3Table 4. Il n'a pas été mis en évidence d'interaction avec le propranolol, la flunarizine, le pizotifène ou l'alcool. Elderly (over 65) Experience of the use of Sumatriptan in patients aged over 65 years is limited. Each 0.5 mL of Sumatriptan Succinate Injection 12-mg/mL solution contains 6 mg of sumatriptan (base) as the succinate salt and 3.5 mg of sodium chloride, USP in Water for Injection, USP. Instruct patients to use injection sites with an adequate skin and subcutaneous thickness to accommodate the length of the needle.Sumatriptan Succinate is not for people with risk factors for heart disease unless a heart exam is done and shows no problem. Proportion of Patients with Cluster Headache Relief by Time in Studies 4 and 5Figure 1. Sumatriptan is used to treat migraines and cluster headaches in adults. Sumatriptan is not recommended for use in children and adolescents as sumatriptan injection has not been studied in these age categories.

A second 6-mg dose should only be considered if some response to a first injection was observed.An autoinjector device is available for use with 4-mg and 6‑mg prefilled syringe cartridges. L'association du sumatriptan avec les inhibiteurs de la monoamine-oxydase (IMAO) est contre-indiquée. Do not discard the auto-injector. Ask your doctor how long you should wait between your doses of these drugs.If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Therefore, the use of Sumatriptan Succinate Injection in patients receiving MAO-A inhibitors is contraindicated Because their vasospastic effects may be additive, coadministration of Sumatriptan Succinate Injection and other 5‑HTCases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors Data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have not detected an increased frequency of birth defects or a consistent pattern of birth defects among women exposed to sumatriptan compared with the general population In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.